BCRX

Berotralstat (BCX7353)

Eliminate or reduce attacks in HAE patients

PDUFA date

Exp Date

December 3, 2020

Amp Volatility Score

N/A

Catalyst Info & Data Links

MECHANISM OF ACTION

  • Our lead compound, ORLADEYO™ (berotralstat), is designed to be an oral, once-daily capsule that prevents attacks by inhibiting plasma kallikrein.

Updated by MV

#HAE #Hereditary Angiodema #Berotralstat  #BCX7353 #rare genetic diseases #BCRX

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

BCRX - MHRA Grants HAE Patient...

#BCRX "announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted oral, once-daily berotralstat a positive scientific opinion through the Early Access t...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon